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Anderson–Fabry disease, an inherited deficiency in the
lysosomal enzyme a-galactosidase A, is characterized by the
progressive accumulation of globotriaosylceramide (Gb3),
also known as CD77. We sought to clarify the pathogenesis of
Fabry disease by establishing a cell model of this disorder.
The expression of a-galactosidase A was transiently silenced
by RNA interference in HK2 and primary human renal
epithelial cells and stably silenced in HK2 cells by retroviral
transfection with small hairpin RNA. All of the silenced cells
had histological similarities to cells of patients with Fabry
disease. The cells had reduced viability, significant
accumulation of intracellular Gb3, and a modest but
significant increase in membranous Gb3 expression
compared to nonsilenced cells. When silenced HK2 cells were
reconstituted with agalsidase-a, a protein used for enzyme
replacement therapy, they decreased their membranous
CD77 expression to levels indistinguishable from those of
nonsilenced cells. Because plasma and urinary Gb3 levels are
not reliable biomarkers for Fabry disease, our study suggests
that membranous CD77 levels mirror Gb3 tissue load and
that CD77 expression levels may be used to monitor the
efficacy of enzyme replacement therapy.
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Anderson–Fabry disease (AFD) is an inherited lysosomal
storage disorder caused by a defect in the synthesis of a-
galactosidase A (a-Gal A, EC 3.2.1.22).1 This enzyme, also
known as ceramidetrihexosidase, is responsible for the
degradation of complex lipids. Mutations in the a-Gal A gene
(located at q22.1 of the X chromosome) obstruct the effective
breakdown of such lipids, which then accumulate in body
tissues and lead to clinical symptoms.2 The predominant
accumulated lipid in AFD is globotriaosylceramide (Gb3),
which is identical to the membrane antigen CD77.3–6
Enzymatically active a-Gal A degrades Gb3 to compounds
with a lower molecular weight, namely galactose and
lactosylceramide. As a result of the enzyme defect, Fabry
patients accumulate Gb3 in various cells and tissues such as
blood, lymph vessels, neurons, myocardial cells, valvular
fibrocytes, podocytes, and renal tubular epithelial cells (TECs).
Signs and symptoms that characterize Fabry patients vary
in appearance and intensity. Owing to the location of the
gene on the X chromosome, male patients are considered to
be predominantly affected by the clinical symptoms of this
severe disease. Nevertheless, most female carriers also exhibit
signs of the disease, albeit to a highly variable degree. The
clinical spectrum includes kidney impairment, pain, hypo-
and anhidrosis, exercise intolerance, skin rashes (angio-
keratomas), corneal whirling, gastrointestinal and heart
problems, nervous system disorders, and psychological signs.
Renal manifestations are observed relatively early during the
course of the disease with a progressive route toward end-
stage renal failure. Proteinuria, isothenuria, and azotemia are
common signs that lead to renal insufficiency. Biopsy
specimens reveal intracytoplasmatic glycosphingolipid accu-
mulation, which affects mainly podocytes and TECs.
According to Sessa et al.,7 ‘The age-related evolution of renal
pathology in Fabry disease is closely correlated with
progressive intracellular deposition of glycosphingolipid
and ultimately leads to end-stage renal failure’. Recently,
Ohshima et al.8 generated an a-Gal A knockout mouse that
remained clinically normal at 80 weeks of age and showed no
evidence of organ failure. These findings indicate that the
pathophysiological processes underlying AFD are different in
mice and men.
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The aim of this study, therefore, was to enlighten the
pathogenic mechanism of AFD by establishing a cellular
model on the basis of human cells. TECs, glomerular
epithelial cells, and immortalized proximal TECs (HK2 cells)
were isolated and the a-Gal A gene was silenced using
small interfering RNA (siRNA)9 and small hairpin RNA
(shRNA) sequences.10–12 Alterations in intracellular Gb3 and
membrane-bound Gb3 (CD77) were measured by flow
cytometry (FACS analysis). Further investigations on these
genetically modified human ‘Fabry cells’ disclosed significant
findings about their proliferation rates and CD77 membrane
expression when subjected to enzyme replacement therapy
(ERT).
In analogy to patients with AFD, our in vitro results
confirm a correlation between local Gb3 accumulation, CD77
overexpression, and a-Gal A downregulation. Comparative
analysis of our results can therefore shed light on the
pathogenic basis of AFD and the impact of Gb3 accumula-
tion on cell viability.
RESULTS
Successful silencing of a-Gal A expression in TECs and HK2
cells
To downregulate a-Gal A expression in human TECs (HK2
cell line and primary cultured TEC), the siRNA technique
was applied as detailed in Materials and Methods.9 Four
different siRNA oligonucleotide sequences were synthesized
on the basis of the human a-Gal A mRNA. Three of the
four sequences were efficient in degrading a-Gal A mRNA
in TEC, resulting in a reduced gene expression (Figure 1a).
In a further attempt, a combination of these siRNA
sequences was used to achieve complete blockage of a-Gal
A expression. In fact, a combination of S1, S3, and S4
oligonucleotides resulted in complete gene silencing
after 1 day of siRNA incubation lasting for 2 days (Figure
1b). On day 5 after incubation, a-Gal A expression was
completely restored as shown for the Hk2 cell line in
Figure 1b. Similar results were observed for TECs (data not
shown).
Furthermore, we demonstrated complete downregulation
of protein expression in TEC and HK2 on day 2 after siRNA
transfection (Figure 1c). Reverse transcriptase PCR analysis
of the a-Gal A mRNA in isolated peripheral blood mono-
nuclear cells (PBMCs) from patients with AFD served as a
control (Figure 1d).
To obtain stable silencing of a-Gal A mRNA, the shRNA
technique was applied. Three different shRNA sequences
were synthesized and cloned into the pSM2c-expressing
vector. Stable a-Gal A silencing was achieved by transducing
the recombinant retroviral vectors into TECs. The transfec-
tion of the three vectors in TECs showed a different efficiency
concerning the stable silencing of the a-Gal A gene
expression. Over a period of 60 days, a-Gal mRNA was not
detected in cells transfected with shRNA V1 (Figure 2a).
Furthermore, silencing of a-Gal A using shRNA vector 1
resulted in a massive reduction of a-Gal A protein
expression in all human renal epithelial cells studied
(glomerular epithelial cells in Figure 2b; HK2 and TEC in
Figure 2c). Agalsidase-a (Replagal) served as a positive
control.
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Figure 1 | Successful silencing of a-Gal expression in primary
TECs and HK2 kidney cell lines by siRNA transfection. (a) a-Gal A
mRNA (425 bp) is degraded by a-Gal A-specific siRNAs in TEC.
Different a-Gal A siRNA sequences (S1, S2, S3, and S4, respectively)
show distinct blocking efficiencies, the highest being with
sequence 1. Laminin siRNA (siL) served as a positive silencing
control (TEC (lam.), 250 bp). M: 50 bp marker. (b) A combination of
the three efficient siRNA sequences (S1, S3, and S4) leads to rapid
and complete suppression of a-Gal A expression by HK2 cells. This
combination of silencer RNAs is even more efficient than using
sequence 1 alone (S1). Five days after siRNA transfection, the cells
resynthesize a-Gal A mRNA, which can be detected by RT-PCR.
The expression of a-Gal A mRNA is not influenced by reagents
used to transfect the HK2 cells (negative control). b-Actin served
as a control for the integrity of the mRNAs. M: 100 bp marker. (c)
Western blot of TECs and HK2 cells, which were tested for a-Gal A
expression 2 days after siRNA transfection. The protein appears in
untreated cells at about 50 kDa (TEC and HK2). Almost no a-Gal A
was detected in transfected cells (siTEC and siHK2). (d) Using
RT-PCR, peripheral blood mononuclear cells (PBMCs) from
patients with AFD were compared with those of a healthy subject
(pos.). a-Gal A mRNA (425 bp) could be detected only in the PBMC
of the healthy person, but was absent in Fabry PBMC (1–5). The
same PBMC mRNAs were tested for b-actin expression (250 bp),
which served as a control for the integrity of the mRNA. M: 50 bp
marker. AFD, Anderson–Fabry disease; RT-PCR, reverse
transcriptase PCR; TECs, tubular epithelial cells.
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Detection of Gb3 accumulation in silenced epithelial cells by
electron microscopy and FACS analysis
When we investigated the morphology of the genetically
a-Gal A ‘silenced’ TEC by electron microscopy, numerous
osmiophilic intracellular inclusions were detected, a typical
histologic feature of Gb3 cell storage in patients with
AFD.13,14 As shown in Figure 3a, the inclusions in our
cellular model resemble myelin figures, suggesting intracel-
lular storage of Gb3 as described earlier by Henry et al.13
Using FACS analysis, both cell lines showed a reproducible,
almost twofold, increase in Gb3 expression when a-Gal A was
downregulated (Figure 3b).
Antiproliferative effects of a-Gal A silencing
To determine the impact of a-Gal A silencing on cell growth
and viability, the proliferation rate of ‘silenced HK2 and TEC’
was examined. In the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) proliferation assay, both cell
lines showed a significant reduction in viability of around
50% (Po0.0001) (Figure 4a and b). The control vector had
no impact on cell vitality. Thus, cell growth is greatly reduced
under silencing conditions, suggesting a putative patho-
mechanism for the renal manifestations in AFD.
CD77 detection on HK2 and TECs
Apart from the intracellular deposition of Gb3, FACS analysis
of non-permeabilized epithelial cells revealed a remarkable
membranous Gb3 expression (antigen CD77) as shown
earlier in lymphocytes.6
HK2 and renal epithelial cells were examined by FACS
analysis for CD77 expression under conditions of a-Gal A
deficiency. All modified cell lines significantly upregulated
CD77 expression when compared with non-transfected cells
(Po0.05, Figure 5a and b). Furthermore, immunostaining of
CD77/Gb3 demonstrated that the a-Gal A ‘silenced’ cells
showed a remarkable upregulation of CD77 membrane
expression (Figure 5c–f). siRNA control oligonucleotides
and transfection reagents did not affect the target cells.
Therefore, FACS analysis of CD77 appears to be an
appropriate method to detect enzyme deficiency.
CD77 expression on PBMC from Fabry patients
To determine whether these in vitro findings can be
reproduced in the in vivo situation, PBMCs were isolated
from Fabry patients and healthy subjects and analyzed by
flow cytometry. These cells also showed a significant CD77
upregulation in comparison with healthy subjects
(P¼ 0.0003, Figure 6) (n¼ 18 per group). In fact, the average
percentage of cells expressing membranous Gb3 (CD77) was
approximately four times higher in Fabry patients compared
with non-Fabry controls (Figure 6b).
Downregulation of CD77 membrane expression by ERT
On the basis of the fact that membranous Gb3 expression is
associated with a reduced a-Gal A activity, we suggested that
ERT results in the downregulation of Gb3. Therefore, we
investigated membranous Gb3 expression in relation to ERT
with agalsidase-a (Figure 7). a-Gal A silencing with shRNA
in HK2 cells had already shown a significant CD77
overexpression in comparison with culture control
(Po0,05). Treatment of HK2 cells with 10 mg/ml agalsi-
dase-a over 3 days resulted in a remarkable downregulation
of CD77 membrane expression to levels almost similar to
untreated (non-silenced) cells (Po0.05, Figure 7).
DISCUSSION
a-Gal A silencing in TECs and HK2 cells
In this study, we established a cellular model of AFD by a
complete siRNA silencing of a-Gal A expression. This
method is based on the RNA interference phenomenon,
according to which cells degrade mRNAs with sequence
homology to the inserted double-stranded RNAs.9
a-Gal A production was ‘silenced’ in TECs and HK2 cells
in analogy to Fabry patients. In the performed western blots, a
single band of about 50 kDa could be observed in lysates of
1 2 V1 V1 M
55
43
(kDa)
siRNA1 shRNA-V1
α-Gal
β-Actin
V2
TEC
TEC HK2 shTEC shHK2
Tubulin
(53 kDa)
α-Gal
(50 kDa)
200 100
Replagal (ng) Glomerular epithelial cells
TEC
–
V3 1 2 V2V3
-
-
Figure 2 | Stable silencing of a-Gal A in HK2 and primary
kidney cells by short hairpin RNAs. (a) A stable degradation of
a-Gal A mRNA is achieved with shRNAs. TECs were transfected
with three different recombinant vectors expressing a-Gal A-
specific shRNA sequences (V1, V2, and V3). Cells transfected with
sequence 1 (V1) showed a complete knockout of a-Gal A gene
expression. (b) Western blots were performed to demonstrate the
efficient reduction of a-Gal A protein in primary kidney cells.
Although a stable transfection with shRNA vector 1 (shRNA-V1)
strongly reduced the amount of a-Gal A protein, complete
inactivation of the enzyme was achieved by a transient
transfection with the siRNA 1. Recombinant a-Gal A (Replagal, 100
and 200 ng, respectively) served as a positive control (for the
rabbit a-human Gal A antiserum). (c) Western blot analysis
demonstrated that transfected TECs and HK2 (shTEC and shHK2)
do not express a-Gal A protein (50 kDa), as do the native HK2 cells
and TECs. b-Actin (Figure 2a) and tubulin (Figure 2c) served as
controls for both the integrity of the RNA and the protein lysates,
respectively. M: 100 bp marker. shRNAs, short hairpin RNAs; TECs,
tubular epithelial cells.
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untreated TEC, which was absent in cells transfected with
siRNA. Although it has been reported that the molecular mass
of monomeric a-Gal A from tissues is 46 kDa,15 our data are
in accordance with an earlier publication of Ledonne et al.,16
who characterized a-Gal A from cultured Chang liver cells
and the commercially available recombinant enzyme Fabra-
zyme or Replagal.17 Indeed, there are certainly differences in
the glycosylation pattern of cellular, tissue, and secreted a-Gal
A.18 As a-Gal A and B are closely related enzymes19 and a-Gal
B has a slightly lower molecular weight (46 kDa), in some
cases, the two homologous enzymes may be confused with
each other. However, the effect of gene silencing through
siRNA was not long lasting (until 5 days of culture, with a
maximum at day 2). Our data are in accordance with those of
Chiu and Rana,20 who demonstrated that siRNAs can
suppress protein expression up to 66 h, with a maximum
effect at 42 h post-transfection. This time-dependent effect
was seen as a time lag between mRNA degradation and half-
life of the protein expressed from the targeted gene. Thus, our
results also show that the half-life of a-gal A is short.
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Figure 3 | Upregulation of intracellular Gb3 after a-Gal silencing in TEC and HK2. Electron micrograph of a tubular epithelial cell after 2
months of stable a-Gal A silencing with shRNA. The lysosomes contain inclusions (arrows) that are pathognomonic for AFD (a). In a higher
magnification, these inclusions revealed the typical ultrastructure of concentric arranged lamellae (arrows, b), which are in accordance with
the lamellar deposits in human organs with Fabry disease. Even if cellular inclusions could be found in the control cells also (arrow, c), these
missed the typical lamellar ultrastructure in higher magnifications (d). After membrane permeabilization, HK2 and TECs were tested for
intracellular Gb3 expression under conditions of a-Gal downregulation (e). An almost 1.5- to 2-fold increase in intracellular Gb3 was
observed (from 36.6 to 58.1% in HK2 cells and from 23.95 to 44.5% in TECs, representative examples). AFD, Anderson–Fabry disease; shRNA,
short hairpin RNA; TECs, tubular epithelial cells.
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Otherwise, the breakdown of the a-gal A mRNA would not
have induced a measurable effect on the protein level.
To establish a stable model for a-Gal A gene silencing,
shRNAs were designed and cloned into the retroviral
expression vector pSM2c. The silencing mode depends on
the complementation of shRNA and its target gene.21,22 The
transfection of the specific vectors into the HK2 and tubular
or glomerular epithelial cells induced a stable silencing of
a-Gal A expression and translation, as the cells were genetically
modified to constantly produce siRNA sequences without
external intervention. When compared with kidney cells from
patients with AFD, our cellular model presented identical
histomorphological features. Electron microscopy revealed
numerous inclusions in TEC, which consisted of membrane
arrays resembling myelin features. These inclusions have been
described earlier and are characteristics for AFD.13,14
Gene silencing through shRNAs23,24 has been widely used
in vivo and in vitro.25–28 In the case of AFD, a stable silencing
of a-Gal A in kidney cells by shRNAs directly reflects the
situation in the kidneys of Fabry patients, which obviously
cannot simply be reproduced by an a-Gal A knockout
mouse.8,29 As shown by Ohshima et al.8,29, a-Gal A /0 mice
remained without clinical manifestations at 80 weeks of age
and showed no signs of organ failure, in contrast to Fabry
patients who suffer from painful and fatal disorders at an
early age of life. Furthermore, the pattern of Gb3 accumula-
tion in kidney cells in a-Gal A knockout mice was different
from that in patients with AFD. In our silenced kidney cells,
we demonstrated not only a nearly twofold intracellular
accumulation of Gb3, but also similar ultrastructural features
to those seen in patients with AFD. Moreover, we have shown
a significant reduction in the vitality of a-Gal A-silenced cells,
in contrast to other in vitro models with artificially prolonged
cell survival.30
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Figure 4 | Vitality of TEC and HK2 after a-Gal A silencing. a-Gal
A silencing reduces the proliferation rate of TECs (a) and the HK2
cell line (b). After 2 months in culture, the vitality of the cells was
tested with an MTT proliferation assay before (culture) and after
(shRNA) shRNA transfection. The control vector had no influence
on the viability of the target cells (values given as mean±s.d.;
*Po0.0001 versus culture, Mann–Whitney U-test). MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; shRNA,
short hairpin RNA; TECs, tubular epithelial cells.
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Figure 5 | Effect of a-Gal A silencing on CD77/Gb3 expression
in TEC and HK2 cells. Flow cytometric analysis of CD77/Gb3
expression in TECs (a) and HK2 cells (b) 2 days after siRNA
silencing. The silencing of a-Gal A by siRNA results in a significant
upregulation of CD77, on the membrane of both HK2 cells and
TECs. Transfection reagents alone had no effect on CD77
expression (data not shown). (Values given are mean±s.d.;
*Po0.05, Mann–Whitney U-test). (c–f) Immunostaining of Gb3 in
TECs and HK2 cells. a-Gal A ‘silenced’ TECs (d) and HK2 (f) cells
demonstrate higher expression of Gb3 in comparison with non-
transfected cells (c and e). The membrane distribution of positive
signal reflects the upregulation of membranous CD77/Gb3
(arrows). TECs, tubular epithelial cells.
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Thus, this cellular model can serve as a tool to investigate
the pathomechanism of AFD.
CD77 expression on cells with a-Gal A deficiency
Further investigation of Gb3 accumulation in the genetically
‘silenced’ kidney cells showed a nearly twofold upregulation of
the accumulating molecule. Interestingly, when membranous
Gb3 expression was measured, a statistically significant, almost
twofold, increase was demonstrated. Maloney and Lingwood6
have linked the Gb3 with the membrane antigen CD77, which
is a cellular receptor for verotoxin. Verotoxin is a potent
enterotoxin of enterohaemorragic E. coli, which induces acute
renal failure.31,32
A further analysis of membranous Gb3 (CD77) expression
in cells isolated from Fabry patients demonstrated results
identical to our cellular model. A study in PBMC of 18 patients
with AFD and 18 non-Fabry controls revealed that 7.7% of the
Fabry PBMCs expressed the CD77 antigen, whereas the
corresponding expression on non-Fabry cells was significantly
lower (2.0%). This significant upregulation was comparable
with that detected in genetically modified primary kidney and
HK2 cells and demonstrated the coherence of a-Gal A
knockout and CD77 increase. Although this is the first study
to quantify CD77 expression in relation to a-Gal A down-
regulation, earlier pathoanatomic observations support our
findings.33 Indeed, Askari et al.33 confirmed the existence of
Gb3 in non-lysosomal cellular compartments and membranes
with predominance in the heart and the kidney.
Flow cytometric analysis of CD77 expression on lympho-
cytes has been the object of various investigations.32,34–36 In
our study, the quantitative determination of CD77 revealed
notable concentration differences among the individual
Fabry patients (2–21%), which may be caused by different
a-Gal A levels, due to the great variety of a-Gal A gene
mutations. In contrast to the assumption37 that the plasma
Gb3 levels reflect the Gb3 tissue load, Young38 recently
showed that Gb3 in plasma and urine cannot be used as a
reliable biomarker for AFD especially in patients with the
N215S mutation and many heterozygotes. Our trials suggest
CD77 on PBMC to be an alternative and easily accessible
indicator of Gb3 tissue load.
We have demonstrated here that a-Gal A deficiency affects
not only intracellular, but also membranous, Gb3 expression.
Furthermore, we detected Gb3 not only on the lymphocyte
surface as described earlier,6 but also on resident kidney cells
such as TECs and HK2. It has been proven in other cell
culture settings that CD77 may function as a receptor and
signal transmitter for apoptosis or necrosis,31,39–41 and this
indicates a further function of antigen CD77 that could be
critical for the renal cell homeostasis.
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Figure 6 | CD77 overexpression on PBMC of patients with AFD. (a) PBMCs from Fabry patients and healthy subjects were tested by flow
cytometry for membrane expression of CD77. The number of CD77-positive PBMCs from Fabry patients is upregulated (21.18%) compared
with healthy subjects (example of Fabry patient). (b) A study of 18 Fabry patients and 18 healthy subjects demonstrating a significant CD77
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Figure 7 | Modulation of CD77 expression on HK2 cells by ERT.
CD77 (Gb3) expression of transfected and untreated () HK2 cells
was examined by FACS analysis before and after ERT. Stable
silencing of a-Gal A for more than 2 months with shRNAs caused a
significant CD77 increase on the cell membrane (shRNA). The
administration of 10 mg/ml of agalsidase-a reduced the expression
of CD77 similar to the level of non-transfected cells (shRNAþ ERT)
(values given are mean±s.d.; *Po0.05 versus untreated HK2,
wPo0.05 versus shRNA HK2, Mann–Whitney U-test). ERT, enzyme
replacement therapy; FACS, flow cytometry analysis; shRNA, short
hairpin RNA.
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Furthermore, our results suggest that CD77 detection
might help to monitor the efficacy of ERT. In Europe, two
recombinant protein patterns containing a-Gal A, agalsidase-
a, and agalsidase-b are approved for the administration of
ERT at different doses (0.2 and 1 mg/kg, respectively,
biweekly). Taking into consideration the high costs of ERT
(around 160,000 US $ per year42), a need for a precise
monitoring of the therapy with recombinant a-Gal A is
emerged. Aerts et al.43 recently suggested deacylated Gb3,
globotriaosylsphingosine, as a marker for clinical management
in AFD. Although this circulating lyso-Gb3 is significantly
increased in hemizygous Fabry male patients, it remained only
partially responsive to ERT with recombinant a-Gal A.
By means of our cellular model, we could demonstrate
that the CD77 expression is upregulated, when the expression
of a-Gal A is blocked. After the addition of agalsidase-a to
the HK2 cells, CD77 was downregulated to the level of the
untreated control cells. Membranous Gb3 (CD77) could
therefore be a useful biomarker, not only for the severity of
AFD and Gb3 tissue loads, but also for monitoring ERT.
Further trials are necessary to elucidate the role and
importance of CD77 in the pathophysiology and treatment
of AFD.
MATERIALS AND METHODS
Antibodies and reagents
Throughout the study, the following antibodies and detecting
reagents were used: rabbit anti-a-galactosidase A polyclonal anti-
body (200 mg/ml; Santa Cruz Biotechnnology, Santa Cruz, CA, USA)
is raised against amino acids 326–429 mapping at the C terminus of
a-gal A of human origin. Chicken anti-human a-gal A and rabbit
anti-chicken IgY (horseradish peroxidase) were purchased from
GeneTel laboratories (Madison, WI, USA). Monoclonal rat anti-
human CD77 antibody (clone 38–13; 5 mg/ml) and mouse anti-rat
IgM fluorescein isothiocyanate antibodies were obtained from AbD
Serotec LTD (Kidlington, UK). Affinity-purified rat IgM isotype
control (500 mg/ml) was purchased from eBioscience (San Diego,
CA, USA). The antibodies used for the detection of apoptosis and
necrosis (annexin V and propidium iodide) were purchased from
BD Biosciences (Franklin Lakes, NJ, USA). Agalsidase-a was
purchased from Shire (Cologne, Germany).
Primary cells and cell lines
Tubular epithelial cells and glomerular epithelial cells were isolated
from human kidneys with the use of collagenase provided by Sigma
(Saint Louis, MO, USA) according to our protocol.44 The HK2 cell
lines (proximal TECs that are immortalized through HPV 16 E6/E7)
were obtained from ATCC (Manassas, VA, USA). The cells were
maintained in Dulbecco’s modified Eagle medium/Ham’s F12
medium (Gibco BRL, Paisley, UK), supplemented with 5% fetal calf
serum, 10mg/ml human epidermal growth factor (Sigma), 1 M 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (Gibco BRL), 50 ng/
ml Gentamycin (Sigma), 50 mg/ml Amphotericin (Sigma), and
hormone mixture (500 ng/ml L-epinephrine, 250 ml 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid buffered saline solution,
500 ng/ml hydrocortisone, 1 ng/ml prostaglandin E2, and 20 ng/ml
T3). All cells were grown at 371C in a 5% CO2 atmosphere.
Peripheral blood mononuclear cells were isolated from patients
with AFD and from healthy subjects using Biocoll separation
solution (contains Ficoll400; Biochrom KG, Berlin, Germany). All
patients gave their written informed consent according to the
Helsinki protocol. Age and gender of the patients/control group are
listed in Tables 1 and 2, respectively.
Gene silencing through siRNA and shRNA transfection
Four specific siRNA sequences were synthesized on the basis of the
human a-Gal gene. Blocking of the a-Gal expression was achieved
using the RNA interference starter kit (Qiagen, Hilden, Germany)
and the following siRNA sequences:
siRNA 1 (sense: 50-UAAAACCUGCGCAGGCUUCTT-30; anti-
sense: 50-GAAGCCUGCGCAGGUUUUATT-3´); siRNA 2 (sense: 50-
AUCCGACAGUACUGCAAUCTT-30; antisense: 50-GAUUGCAGUA
CUGUCGGAUTT-30); siRNA 3 (sense: 50-UUGCCAUCAAUCAG
GACCCTT-30; antisense: 50-GGGUCCUGAUUGAUGGCAATT-30);
and siRNA 4 (sense: 50-GUGUGGGAACGACCUCUCUTT-30; anti-
sense: 50-AGAGAGGUCGUUCCCACACTT-30).
Table 1 | Characteristics of 18 Fabry patients
Patient no. Sex Age (years)
1 M 49
2 M 46
3 F 6
4 F 73
5 M 15
6 F 45
7 M 12
8 F 17
9 F 57
10 M 51
11 F 11
12 F 18
13 F 29
14 M 32
15 F 50
16 M 53
17 F 20
18 F 70
+ 11F/7M 36
Table 2 | Characteristics of 18 control patients
Patient no. Sex Age (years)
1 M 57
2 F 57
3 F 49
4 M 29
5 F 36
6 F 37
7 M 42
8 F 61
9 F 64
10 M 41
11 F 27
12 F 42
13 M 24
14 F 27
15 F 29
16 M 29
17 F 30
18 F 33
+ 12F/6M 37
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Briefly, cells were transfected with a 20 mM siRNA solution and
incubated with the transfection reagent for the following 15 min at
room temperature. Subsequently, cells were cultured for 24–72 h
at 371C.
Three a-Gal-specific shRNA sequences were designed from
hairpin miRNA and cloned in the retroviral expression vector
pSM2c using the RNAintro shRNA transfection kit (Open
Biosystems, Huntsville, AL, USA). The sequences were as follows:
shRNA 1 (sense: CTGTGAGTGGCCTCTTTAT; antisense:
ATAAAGAGGCCACTCACAG); shRNA 2 (sense: GGACTGAAGC
TAGGGATTTA; antisense: TAAATCCCTAGCTTCAGTCC); and
shRNA 3 (sense: CTGGGCTGTAGCTATGATAA; antisense: TTAT
CATAGCTACAGCCCAG).
The PT67 cell line (Clontech laboratories, Mountain View, CA,
USA) was transfected for 24 h with one of the three recombinant
retroviral vectors (see above), resulting in the production of
infectious replication-incompetent retroviruses. Next, puromycin
was used to select stable clones. After 2 weeks, the produced virus
was collected in order to transfect TEC and the HK2 cell line. The
target cells were then treated with puromycin for the selection of
stable clones resulting in stable suppression of a-Gal RNA
expression and translation.
RNA extraction
A total of 5 106 cells per pellet were used for RNA extraction. On
reaching confluency, the cultured cells were trypsinized, centrifuged,
and the resulting pellet was further used for RNA isolation. RNA was
isolated from cells using the RNeasy mini kit (Qiagen) according to
the manufacturer’s instructions.
Reverse transcriptase PCR
RNA was isolated from cells (see above) using b-mercaptoethanol,
RLT, and continuous centrifugation (Gibco BRL Superscript II).
One microgram of RNA was further reverse transcribed into cDNAs
followed by amplification of the resulting DNA using PCR.
For reverse transcriptase PCR, the following primers were used:
a-Gal (sense: 50-ACGACATTGATGCCCAGACCTTTGC-30; anti-
sense: 50-AGGAGCAGCCATGATAGCCCAGAG-30); b-actin (sense:
50-ATGGATGATGATATCGCCGCG-30; antisense: 50-TCTCCATGT
CGTCCCAGTTG-30); laminin (sense: 50-GGACCTGGAGGCTCTG
CTGAACTC-30; antisense: 50-GGTCTCACGCAGCTCCTCACTG
TAG-30).
The annealing temperature was 581C for a-Gal-, 64.51C for
laminin-, and 601C for b-actin-specific primer pairs, respectively. All
reagents for the reverse transcriptase PCR were obtained from Gibco
BRL.
Protein isolation and immunoblotting
The cells (2 106 cells per ml immunoprecipitation assay (RIPA)
buffer) were washed with ice-cold phosphate-buffered saline (PBS)
and then lysed with RIPA buffer (50 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, and
0.1% sodium dodecyl sulfate) containing protease inhibitors (2mg of
aprotinin per ml, 2mg of leupeptin per ml, and 1mg of pepstatin A per
ml) for 30 min on ice. After sonication, the lysates were centrifuged at
14,000 r.p.m. for 15 min at 41C. Lysates were immunoblotted with
chicken anti-Gal A or rabbit anti-Gal A (1mg/ml each).
Flow cytometric analysis of Gb3 (CD77) membrane expression
A total of 5 105 cells were centrifuged for 5 min at 1500 g. After the
addition of a-CD77 antibody (20:100), cells were incubated for
45 min at 41C. Cells were washed with PBS and incubated with
the secondary mouse anti-rat antibody (1:100) for 45 min at
41C. Antibody staining was fixed using Dulbecco’s PBS and 1%
formalin. To detect unspecific signals, IgM isotype control (1mg/ml)
was used.
For the detection of intracellular Gb3, cells were initially fixed
and permeabilized with 250ml of BD Cytoxin/Cytoperm solution
(Becton Dickinson, Franklin Lakes, NJ, USA). After an incubation
period of 20 min at 41C, cells were washed twice in saponin buffer
and stained as described above.
Immunophenotyping was performed by FACS (FACS Scan;
Becton Dickinson). The Gb3 and CD77 quantification was
performed by using the Cellquest software (Becton Dickinson).
Approximately 5,000 cells were counted per measurement.
Immunohistochemistry
Cells were seeded on glass coverslips or Lab-Tek chamber slides
(Nunc, Wiesbaden, Germany) and fixed with 4% paraformaldehyde
in PBS for 10 min at room temperature and treated with 0.3%
Triton X-100 in PBS (0.3% PBST) for 5 min. After blocking with
10% normal mouse serum in 0.01% PBST for 1 h, the cells were
incubated with the rat anti-human CD77/GB3 monoclonal IgM
antibody diluted 1:2) in 5% normal mouse serum/0.01% PBST for
1 h at 41C or rat IgM isotype control (diluted 1:100). Antibody
binding was visualized by incubation with a fluorescein isothiocya-
nate-conjugated mouse anti-rat IgM heavy-chain secondary anti-
body (diluted 1:100). The cells were mounted and counterstained
with Vectashield plus DAPI (Vector Laboratories, Burlingame, CA,
USA) and observed with a Zeiss Axiophot fluorescence microscope
equipped with a Sony CCD digital camera.
MTT proliferation test
Cells were grown in 96-well plates in a final volume of 100 ml per
well and then incubated in a humidified atmosphere (371C, 5%
CO2). Ten microliters of MTT labeling reagent was added to each
well (final concentration of 0.5 mg/ml and incubated for 4 h in a
humidified atmosphere). Then, 100 ml of solubilization solution was
added to each well and left overnight. The spectrophotometric
absorbance was measured at 550 nm using a microplate ELISA
Reader (Bio-Rad, Hercules, CA, USA).
Electron microscopy
Human tubular epithelial kidney cells were cultured on filter
membranes. For transmission electron microscopy, the cell layers
were fixed in 2.5% glutaraldehyde in cacodylate buffer (pH 7.2) for
2 h, then fixed in 1% OsO4 for 2 h, and dehydrated in graded
ethanol. After carrying the filter membranes with cells through
propyleneoxid as an intermedium, the samples were embedded in
agar 100 resin (PLANO, Wetzlar, Germany) and submitted to
polymerization at 601C for 48 h. Ultrathin sections were cut
perpendicular to the filter surface with an ultramicrotome (Ultracut
E; Leica, Bensheim, Germany) and ultrathin sections were placed
onto copper grids. Ultrastructural analysis and photomicroscopy
were performed with a transmission electron microscope (model
EM 410; Philips, Eindhoven, The Netherlands).
Statistics
Data were analyzed using the Mann–Whitney U-test to compare
group means. Results are expressed as mean±standard error of
mean (s.e.m.). A P-value less than 0.05 was considered to represent a
significant difference.
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